Splanchnic Nerve Block for Therapy of Chronic Heart Failure (Splanchnic III)
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Splanchnic vasoconstriction may contribute to decompensation of chronic heart failure (HF)
via volume redistribution from the splanchnic vascular bed to the central compartment. This
is a sympathetically mediated reflex and can be interrupted through a splanchnic nerve block
(SNB). We hypothesize that interruption of the efferent/afferent innervation of the
splanchnic vasculature will decrease cardiac congestion in patients presenting with HF. Based
on preliminary safety and efficacy data in acute and chronic heart failure patients with
temporary (<24 h) SNB. Now we will apply a prolonged SNB in chronic heart failure patients
using a long acting agent. We will test the effects of SNB on long term exercise capacitance.